Xcovery Holdings, Inc.

This phase 3 study tests whether a new drug called ensartinib works better than the current standard drug crizotinib for people with a specific type of advanced lung cancer (ALK-positive non-small cell lung cancer). About 290 patients who have had up to one prior chemotherapy but…